Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

BACKGROUND: Randomized trials evaluating programmed cell death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration of therapy is currently unknown due to limited data, and shorter therapies may be effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokorny, Rebecca, McPherson, Jordan P, Haaland, Benjamin, Grossmann, Kenneth F, Luckett, Carolyn, Voorhies, Benjamin Newell, Sageser, Daniel S, Wallentine, Jocelyn, Tolman, Zachary, Hu-Lieskovan, Siwen, Swami, Umang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843310/
https://www.ncbi.nlm.nih.gov/pubmed/33500258
http://dx.doi.org/10.1136/jitc-2020-001781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843310/
https://www.ncbi.nlm.nih.gov/pubmed/33500258
http://dx.doi.org/10.1136/jitc-2020-001781

Ejemplares similares